Kent Oliver
Maria Whitman
The International Myeloma Foundation (IMF) welcomes four of its newest members to the IMF Board of Directors: Director of Strategic Growth at Raanes & Oliver Capital Advisors, Kent Oliver; Managing Partner of Global Commercialization Strategy and Solutions at ZS Associates, Maria Whitman; Director of the Multiple Myeloma Program at Winship Cancer Institute of Emory University, Sagar Lonial, MD, FACP; and Professor of Medicine at Harvard Medical School, Director of Basic and Correlative Science, and Associate Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, Nikhil Munshi, MD.
Sagar Lonial, MD, FACP
Nikhil Munshi, MD
Mr. Oliver is is a long-standing donor, resilient myeloma survivor, advocate, and strong voice for all patients with myeloma and care partners. He has made generous contributions to help create and develop Myelo, the IMF’s AI-powered responsive chatbot, an integral piece of IMF’s Myeloma Knowledge Platform. Diagnosed with myeloma in 2015 at the age of 34, Mr. Oliver’s journey has been marked by compassion, generosity, dedication, and commitment to serving the myeloma community.
Ms. Whitman is a recognized leader who is passionate about advancing health. She works at ZS Associates, a global management consulting and technology firm and one of the IMF’s partners that helped create Myelo. Ms. Whitman is a strategic thought leader in health care, particularly within oncology, cell and gene therapy, and rare diseases, where she has been instrumental in transforming business models to drive innovation and patient-centric solutions.
Dr. Lonial is a distinguished myeloma physician and a leading figure in multiple myeloma research. His research has been instrumental in advancing the understanding and treatment of myeloma. He has conducted extensive studies to investigate the biology of the disease, identify new therapeutic targets, and develop innovative treatment strategies. His work has led to significant breakthroughs in managing the disease, improving patient outcomes.
Dr. Munshi is a recognized international leader and a major force in translational research in multiple myeloma. In addition to his role at Dana-Farber, he is an attending physician at the Brigham and Women’s Hospital and the Boston VA Healthcare system, Harvard Medical School. His research has aimed to understand genomic changes in myeloma; elucidate molecular mechanisms driving the genomic instability in cancer; and improve diagnosis, prognosis, and therapeutics.
